DAYbreak CLL-201: A phase 2 trial of NX-5948 in people with relapsed or refractory CLL/SLL

This trial aims to see how effective the treatment NX-5948 in adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) which has come back after (relapsed) or failed to respond to (refractory) treatment.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT07221500

Trial aim and background  

The aim of this trial is to see how effective the treatment NX-5948 is in people with relapsed or refractory CLL/SLL who have previously received treatment with a BTK inhibitor and a BCL-2 inhibitor. 

NX-5948 is a type of targeted treatment called a BTK degrader  

All people in the study will receive treatment until their cancer gets worse or if there are other reasons to stop it. 

Who can enter 

Adults with relapsed or refractory CLL/SLL may be eligible for this trial.

Locations 

Recruitment is taking place at:

  • Oxford University Hospitals NHS Foundation Trust, Oxford
  • The Royal Marsden NHS Foundation Trust, London
  • The Christie NHS Foundation Trust, Manchester

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT07221500

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.